| Julien Mazieres |
|
DeLLphi-300 phase I study (Tarlatamab in previously treated #SCLC) long-term outcomes and intracranial activity: ORR 25%, mDoR 11.2 m, median OS 17.5 m, intracranial disease control 87.5%. DeLLphi-304 trial currently recruiting patients |
Link |
| Masahiro Torasawa |
|
【再発小細胞肺がんの標準治療が変わる】DeLLphi-304 phase3 vs ルビネクテジン／トポテカン／アムルビシン タルラタマブ群がOSにおいて統計学的に有意かつ臨床的に意義のある改善 |
Link |
| Rami Manochakian |
|
DeLLphi304 trial of IMDELLTRA (TARLATAMAB) vs Chemotherapy in 2nd line Tx for patients with SmallCell LungCancer shows: Statistically Significant & Clinically Meaningful Improvement in Overall Survival |
Link |
| Dr. Antonio Calles |
|
Tarlatamab improves survival in 2nd line SCLC. DeLLphi-304 results demonstrated statistical significant and clinically meaningful improvement in overall survival compared to standard of care chemotherapy. |
Link |
| Balazs Halmos |
|
DeLLphi-304 - OS benefit with tarlatamab over SOC in 2nd line ES-SCLC. Targeting DLL - i call that a good DEAL! |
Link |
| Alfredo Addeo MD |
|
Breaking: The Phase 3 DeLLphi-304 trial met its primary endpoint: IMDELLTRA significantly improved overall survival vs SOC in SCLC patients post-platinum. A major step forward for this hard-to-treat disease. |
Link |
| Dr Amol Akhade |
|
Big win in SCLC Amgen's IMDELLTRA (tarlatamab), a DLL3-targeting BiTE, shows OS superiority over chemo in 2L SCLC (DeLLphi-304). First-in-class, tumor-selective T-cell engager |
Link |
| Manuel Dómine |
|
DeLLphi 304: 1st Phase 3 Trial Showing Substantial Survival Advantage vs Chemotherapy (tarlatamab vs 2nd line CT in relapsed SCLC. |
Link |
| Dipesh Uprety MD |
|
Press Release: DeLLphi-304 is a global Phase 3 trial in pts with extensive stage SCLC. Pts were randomized to tarlatamab or SOC chemo in 2L setting ↑OS with tarlatamab |
Link |
| Michael Duruisseaux |
|
Phase 3 DeLLphi-304 is clinical trial evaluating Tarlatamab vs SOC chemo in SCLC who progressed after front-line platinum-based chemo met its primary endpoint of OS. |
Link |